medication, read plainlylast verified 2026-09-25

antidepressants and emotional blunting

the mood is better and something else is gone: you do not cry at the film, you do not feel the thing you used to feel when they walk in, the good news lands flat. people describe it in the same words on every forum, and for a long time the clinical answer was that it was the depression. it is partly the depression. it is also, on the best evidence there is, partly the drug, and the two are hard to pull apart. here is what has been counted, the experiment that separates them, the case for the other side, and what to bring to the appointment.

five questions, answered from the record

how many people get this?^[1]

nearly half, in the only large count. of 669 depressed patients on antidepressants who answered the Oxford questionnaire, 46 percent reported emotional blunting: 52 percent of the men and 44 percent of the women. it did not differ by drug, though it looked less frequent with bupropion, and the authors say the sample was too small to be sure of any between-drug difference. it is an internet survey with self-rated symptoms, which is the limitation the authors name first. it is still the number.

is it the drug or the depression?^[1]^[2]

both, and the same survey shows it. blunting scores tracked depression scores closely (r 0.52): people who were still depressed were much more blunted than people who were not. but people whose depression score was in the normal range (140 of them) still scored higher on blunting than 150 recovered people who were not taking anything. the authors conclude it cannot be described simply as a side effect, but also as a symptom, and that more blunting goes with a poorer quality of remission. the qualitative study that built the questionnaire found most participants felt able to tell the two apart in themselves.

is there an experiment that separates them?^[3]

one. sixty-six healthy volunteers with no depression took 20 mg of escitalopram or placebo for at least three weeks, double-blind. the escitalopram group showed lower reinforcement sensitivity, meaning their learning responded less to reward and punishment, on two separate tasks; nothing else in memory, inhibition or flexibility changed. the authors say this may be the blunting that patients describe. it is 66 people and a lab measure, not a feeling, and it is the cleanest evidence that the drug does something on its own.

do people mind?^[1]^[2]

less uniformly than the forums suggest. among the blunted patients in the survey, 37 percent saw it as negative and 38 percent as positive, with the rest in between; men were more negative than women, and people with more blunting were more negative about it. the qualitative study found the same split, and found that it plays a role in whether people keep taking the drug. if you are on the “can’t feel my partner” end of it, you are in a real group. if you are relieved to feel less, you are in one too.

what do prescribers do about it?^[4]

the scoping review of 25 studies names two common clinical strategies: lowering the dose, or switching to a different antidepressant. it also says the literature has not separated blunting-as-symptom from blunting-as-side-effect, so neither strategy has been tested against the alternative that the numbness is the depression itself. this page does not tell you to do either. it tells you what the options in the literature are, so that the conversation with your prescriber starts from the record. do not lower a dose on your own.

what “blunting” means in the studies

the review’s definition is the one to hold on to: a persistent diminution in both positive and negative feelings, which people can tell apart from their acute symptoms.^[4] both directions is the tell. depression takes the good feelings; the thing people describe on the drug takes the bad ones too, and that is what the questionnaire was built to catch.^[2] the healthy-volunteer study puts a mechanism under it: after three weeks, the escitalopram group’s learning responded less to both reward and punishment, and nothing else about their thinking changed.^[3] the “lost feelings for my partner” posts are the same phenomenon with a face on it; none of the abstracts read for this page measured relationship feeling separately, so there is no number for that, only the 46 percent it sits inside.^[1]

the other direction

the strongest case against reading this as a drug effect is in the survey’s own numbers. blunting tracked depression score at r 0.52, and the most blunted people were the most depressed; the authors’ own conclusion is that it is also a symptom of depression, and that more of it means a poorer remission, which is an argument that the treatment has not finished, not that it has gone wrong.^[1] the count is a self-selected internet sample with no untreated depressed comparison group, so “46 percent” is a rate among people who chose to answer a questionnaire about emotional side effects.^[1] the qualitative study drew partly on patient websites, where people go to describe a problem.^[2] the healthy-volunteer result is 66 people and a task score, not a lived feeling, and it did not test whether the effect fades.^[3] the review says plainly that the literature has not made the distinction that this whole page turns on.^[4] and 38 percent of the people who had it called it a good thing.^[1]

what this page will not do

it will not tell you to lower a dose, stop, or switch. the two strategies in the literature are untested against each other and against doing nothing, and the mood the drug is holding is the thing at risk if a change goes wrong. if the missing feeling is sexual rather than emotional, or both, the SSRI sexual side effects page has the rates by drug and the regulator’s warning on symptoms that persist after stopping. if the drug seems to have stopped working altogether rather than flattened you, when an antidepressant stops working is the page for that.

what to ask your prescriber

“is this the depression, the drug, or both, and how would we tell?”^[1]^[4]

the survey found blunting tracks depression scores and also exceeds them in remitted patients; the review says the literature has never cleanly separated the two. a prescriber who has a way to check, a depression score beside a blunting score over time, is doing what the studies could not.

“can we measure it with the Oxford questionnaire?”^[1]

the OQESA exists for exactly this, and a number at the start beats an impression. it is the instrument the 669-patient survey used.

“if it is the drug, what are the options, and what does each one cost me?”^[4]

the review names dose reduction and switching. both have their own risks, including to the mood the drug is holding up, and neither has been tested head-to-head. the answer should be a plan with a check-in date, not a change made in the room.

“how much of this is a reason to stay, and how much a reason to change?”^[1]^[2]

thirty-eight percent of blunted patients called it positive. a prescriber who asks how you feel about feeling less, rather than assuming, is taking the symptom seriously in both directions.

questions people ask

How common is emotional blunting on antidepressants?

In a survey of 669 depressed patients on antidepressant treatment, 46 percent reported emotional blunting on the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants: 52 percent of men and 44 percent of women. The rate did not differ between antidepressants, though it appeared less frequent with bupropion in a sample the authors say was too small to settle between-drug differences.

Is emotional blunting caused by the antidepressant or by the depression?

Both, on the available evidence. In the 669-patient survey, blunting scores correlated with depression scores (r 0.52), but patients whose depression score was in the normal range still scored higher on blunting than recovered people not taking antidepressants. In a double-blind study of 66 healthy volunteers, three weeks of escitalopram lowered reinforcement sensitivity against placebo, which the authors say may reflect the blunting patients report. A 2023 scoping review of 25 studies found the literature has not separated blunting as a symptom from blunting as a side effect.

Does emotional blunting go away?

The abstracts read for this page do not report how often blunting resolves, either on continued treatment or after stopping. The scoping review describes it as a persistent diminution in both positive and negative feelings and names dose reduction and switching as the common clinical strategies, without evidence comparing them. Whether anything should change is a decision for you and your prescriber, not a page.

Should I lower my dose or switch antidepressants because I feel numb?

This page cannot answer that and does not try. Dose reduction and switching are the two strategies the literature names, neither has been tested against the possibility that the numbness is the depression itself, and both carry risks to the mood the drug is treating. Take the question to the person who prescribes for you. Do not change a dose on your own.

sources

Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. Journal of Affective Disorders 2017;221:31-35. Internet survey of 669 depressed patients on antidepressant treatment and 150 recovered controls, using the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants (OQESA). “The rate of emotional blunting in treated depressed patients was 46%, slightly more frequent in men than women (52% versus 44%)”; “no difference according to antidepressant agent, though it appeared less frequent with bupropion.” Total blunting score 42.83 ± 14.73 in blunted patients versus 25.73 ± 15.00 in controls; correlation with HAD-Depression score r = 0.521; patients with HAD-D ≤ 7 (n = 140) still scored higher (35.07) than recovered controls. “Among the patients with emotional blunting, 37% had a negative perception of their condition and 38% positive.” Conclusion: “emotional blunting cannot be described simply as a side-effect of antidepressants, but also as a symptom of depression.” Limitations: self-evaluation, modest sample for between-drug differences. Two of the four authors are affiliated with Institut de Recherches Internationales Servier, Suresnes, France, a pharmaceutical company, per the PubMed affiliation record. PMID 28628765. https://doi.org/10.1016/j.jad.2017.05.048
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. British Journal of Psychiatry 2009;195(3):211-217. Individual interviews, a group interview, validation interviews and patient-website posts. “There was strong evidence that some people taking SSRIs experience significant emotional symptoms that they strongly attribute to their antidepressant”; described within six key themes, with a seventh for impact on everyday life and an eighth for why participants attributed the symptoms to the drug. “Most participants felt able to distinguish between emotional side-effects of antidepressants and emotional symptoms of their depression.” Conclusion: “a robust phenomenon… playing a role in their decision-making about antidepressant adherence.” The six themes are not listed in the abstract and the full paper was not read for this page. PMID 19721109. https://doi.org/10.1192/bjp.bp.108.051110
Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology 2023;48(4):664-670. 66 healthy volunteers at the University of Copenhagen, escitalopram 20 mg (n = 32) or placebo (n = 34) for at least 21 days, balanced for age, sex and IQ. “Escitalopram reduced reinforcement sensitivity compared to placebo” on two learning tasks; “no other significant group differences on ‘cold’ or ‘hot’ cognition.” “Lower reinforcement sensitivity in response to chronic SSRI administration may reflect the ‘blunting’ effect often reported by patients with MDD treated with SSRIs.” NCT04239339. PMID 36683090. https://doi.org/10.1038/s41386-022-01523-x
Jawad MY, Fatima M, Hassan U, et al. Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature. Human Psychopharmacology 2023;38(4):e2871. Systematic search to 15 March 2022; 25 original studies. “Emotional blunting was described as a persistent diminution in both positive and negative feelings in depressed patients, who could subjectively differentiate it from their acute symptoms. However, the literature lacked the distinction between emotional blunting as a primary symptom of depression or an adverse effect of antidepressants. Common clinical strategies to manage antidepressant-induced emotional blunting included dose reduction or switching to a different antidepressant.” PMID 37184083. https://doi.org/10.1002/hup.2871

adam